The pharmaceutical industry is at an inflection point, where ground-breaking innovation must be translated into transformational value for patients, healthcare professionals and society.
Gilead has blamed a $3.3 billion loss in Q2 on its acquisition of immune-oncology company Forty Seven – but revenues are declining as the pandemic bit into sales of its hepatitis C drugs.
The industry is increasingly aware of the importance of corporate social responsibility (CSR) programmes – and Alex Kalomparis, Gilead’s vice president of public affairs for EMEA, says they
NHS England has announced a deal with AbbVie, Gilead, and Merck, Sharpe and Dohme (MSD) that aims to eliminate hepatitis C from the country - although it has had to drop a 2025 target date
South Korea’s Hyundai Bioscience is preparing to start clinical trials of what it hopes could become the first antiviral treatment for dengue fever, a mosquito-borne viral
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.
